Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe
Reacquiring rights to omaveloxolone from AbbVie looks great business
Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone – which the company is buying back from AbbVie for $330m.
You may also be interested in...
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.